title: [Pharmacogenetics of clopidogrel and its clinical significance].
abstract: The review is devoted to pharmacogenetics of clopidogrel and its value for the clinic. Mechanism of action of clopidogrel and main trials which has proven its efficacy are presented as well as results of main large studies including authors own results demonstrating dependence of clinical efficacy of clopidogrel on carriage of polymorphisms of gene of CYP2C19 which accomplishes metabolism of the drug in the liver. Problems of interaction of clopidogrel with proton pump inhibitors and other drugs as well as ways of overcoming "resistance" to clopidogrel are considered. Clinical efficacy of other P2Y12 receptors of platelets in patients with IHD is characterized in comparison with clopidogrel.
authors.forename: E P
authors.initials: EP
authors.lastname: Panchenko
authors.forename: A L
authors.initials: AL
authors.lastname: Komarov
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D001189:Aryl Hydrocarbon Hydroxylases / Q000378:metabolism*; D001711:Biotransformation / Q000235:genetics; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D004347:Drug Interactions / Q000235:genetics; D004351:Drug Resistance / Q000235:genetics; D006801:Humans; D010597:Pharmacogenetics; D010974:Platelet Aggregation / Q000187:drug effects / Q000235:genetics; D010975:Platelet Aggregation Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D054328:Proton Pump Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine